After a wave of feedback, the accreditor has deferred a ban on use of corporate logos in disclosures of commercial support.
Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.
Pharma's med-ed cut was its fifth in a row. But other income surged, filling the void as the funding picture for CME continued to even out.
New transparency rules set to lay bare financial ties between physicians and pharma will be a mixed bag for medical education, providers say.
Data show detailing pressure and pharmaceutical rep access are still much higher in primary care than in other specialties.
The drug industry dialed back its continuing medical education (CME) grant-giving in 2011, continuing a negative trend of the last few years.
The FDA's opioid REMS safety plan is challenged on two fronts: getting CME providers to offer courses and getting doctors to attend them. Can the agency's scheme educate enough physicians to curb an epidemic?
Over the last four years, drugmakers have slashed support for samples as they rethink what once was an essential part of their marketing mix.
The ACCME awarded provisional two-year accreditation to Lighthouse Learning, the educational content provider which develops and sells CME curricula without accepting commercial funding.
The drug industry's backing of certified CME fell for a third straight year, as registration fees and other income surged, just-released data from ACCME show.
In a sign of industry's ongoing desire to broaden its CME funding outlook, a couple of recently supported educational programs by Pfizer aim to foster practice-based improvement as they seek to advance the science of CME.
A medical society that suggested using pooled funds to handle commercial support for medical education got an earful from industry.
Progenics announced that it will hand over commercial duties on Relistor, a subcutaneous injection for opioid-induced constipation, to Salix Pharmaceuticals, beginning in April. Financial terms include a $60 million upfront payment to Progenics, and another potential $290 million in development and sales-based milestone payments.
Industry support for continuing medical education (CME) has been waning the last two years, but some say the bottom may be in sight.
A new medical education company has opened offering to produce CME that is free of commercial support.
Total commercial support of accredited CME fell 17% to $856 million in 2009, according to ACCME's annual report—marking its second straight year of double-digit declines on a percentage basis.
Several months' worth of dialogue, at times public and heated, between physician groups like the American Heart Association and the ACCME, has resulted in new guidance from the regulator of continuing medical education: Industry scientists, who had been barred from presenting original product-related research at for-credit talks, may now do so as long as provider controls ensure they have zero control over the content.
Medical society journals must ban ghostwritten articles and cannot place ads for drugs next to editorial content discussing those products or their makers under a sweeping ethics code signed by several major medical societies.
A Medscape-sponsored survey of a million physicians participating in online CME found that fewer than 1% perceived bias, regardless of whether or not it was commercially-supported.
Total commercial support of accredited CME dropped 14% to $1 billion in 2008, according to the Accreditation Council for Continuing Medical Education's annual report -- even as the number of physicians participating in CME activities jumped 22% to 10.6 million.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.